Global Hodgkin Lymphoma Treatment Market is anticipated to showcase considerable growth during the forecast period. A significant increase in the intensive research and development of Hodgkin lymphoma treatment along with the increase in the incidence and prevalence of Hodgkin lymphoma is anticipated to be a key factor propelling the growth of the market. Hodgkin lymphoma is a kind of cancer in the body system that affects the lymph nodes and other organs. Mainly, chemotherapy and radiation therapy are the highly adapted therapies adapted to kill the cancer tissues with a high radiation beam. However, due to the lack of technological resources leads to limited treatment.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/hodgkin-lymphoma-treatment-market
In past years, two major classes of drugs; antibody-drug conjugates (ADC) and programmed death 1 (PD-1) receptor inhibitors are labeled as advanced Hodgkin lymphoma. Moreover, clinical trials are conducted with these drugs to improvise results of Hodgkin lymphoma diagnosed patients. Furthermore, multi-agent of Chemotherapy and radiation therapy decreases the risk of relapse and encouraging the HL results. Hence, accelerating the market growth by advancing the Hodgkin lymphoma management with ADC and PD-1 receptor inhibitors. In February 2019, a randomized, multicentre, non-inferiority, and phase3 study had revealed that PET-adapted treatment is found appropriate for the treatment of newly diagnosed advanced Hodgkin lymphoma.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/hodgkin-lymphoma-treatment-market
The increase in the demand for lymphoma treatment and intensive R&D is anticipated to increase the market share. Apart from this, an increase in the number of regulatory approval by the Food and Drug Administration (FDA) plays a significant role in Hodgkin lymphoma treatment market growth. For instance, In March 2017, Merck KgaA had received the US FDA approval for KEYTRUDA (pembrolizumab). KEYTRUDA (pembrolizumab) is a kind of drug which is used for the treatment of adult and pediatric patients having classical Hodgkin lymphoma (CHL). The drug treatment is also suitable for patients who have relapsed after three or more prior lines of therapy.
Recent Developments in Market
In March 2020, Tessa Therapeutics Inc. had launched Tessa Therapeutics TT11. The Tessa Therapeutics TT11 has become the first CAR-T therapy to receive the US Food and Drug Administration (FDA) regenerative medicine advanced therapy (RMAT) designation. CAR-T therapy is set to become useful cell-based therapy in the treatment of Hodgkin’s lymphoma (HL). The launched therapy is anticipated to displace the outdated stem cell transplants as the standard of care by 2024.
Global Hodgkin Lymphoma Treatment Market Segmentation
By Treatment
- Radiation therapy
- Immunotherapy
- Chemotherapy
- Others
Global Hodgkin Lymphoma Treatment Market – Segment by Region
North America
- The US
- Canada
Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Latin America
- Middle East & Africa
Company Profiles
- Bristol-Myers Squibb Co.
- Fresenius Kabi USA, LLC
- Genentech Inc.
- Healthgrades Operating Company, Inc.
- Hikma Pharmaceuticals PLC
- Leadiant Biosciences, Inc.
- LGM Pharma, LLC
- Merck & Co. Inc.
- Mylan N.V.
- NextSource Biotechnology, LLC
- Pfizer, Inc.
- Recordati Rare Diseases, Inc.
- Seattle Genetics. Inc.
- Takeda Pharmaceutical Co. Ltd.
- Teva Pharmaceuticals Industries, Ltd.
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
